NovoCure (NVCR) Shares Outstanding (2014 - 2026)

NovoCure (NVCR) has reported Shares Outstanding (Entity) for 13 consecutive years, with $116.4 million the latest figure, recorded in Q2 2026.

• Quarterly Shares Outstanding (Entity) rose 4.15% year-over-year to $116.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $116.4 million (up 4.15% YoY) and the FY2025 annual result came in at $112.5 million, up 3.66% from the prior year.
• Shares Outstanding (Entity) rose to $116.4 million in Q2 2026 per NVCR's latest filing, from $115.8 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for NVCR reached as high as $116.4 million in Q2 2026 and fell as low as $104.6 million in Q1 2022.
• A 5-year average of $108.8 million and a median of $107.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 1.04% — and 2026, when it advanced 4.15%.
• Year by year, Shares Outstanding (Entity) stood at $105.0 million in 2022, then increased by 1.93% to $107.1 million in 2023, then rose by 1.35% to $108.5 million in 2024, then climbed by 3.66% to $112.5 million in 2025, then climbed by 3.51% to $116.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $116.4 million, $115.8 million, and $112.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.